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OBJECTIVES: Carotid artery stenting is an emerging revascularization alternative to carotid endarterectomy.
However, guidelines have recommended carotid artery stenting only if the rate of periprocedural stroke or
death is, 6% among symptomatic patients and, 3% among asymptomatic patients. The aim of this study is to
evaluate and compare clinical outcomes of symptomatic and asymptomatic patients who had undergone
carotid artery stenting as a first-intention treatment.
METHOD: A retrospective analysis of patients who underwent carotid artery stenting by our interventional
neuroradiology team was conducted. Patients were divided into two groups: symptomatic and asymptomatic
patients. The primary endpoints were ipsilateral ischemic stroke, ipsilateral parenchymal hemorrhage and
major adverse cardiac and cerebrovascular events at 30 days. The secondary endpoints included ipsilateral
ischemic stroke, ipsilateral parenchymal hemorrhage, ipsilateral transient ischemic attack and major adverse
cardiac and cerebrovascular events between the 1- and 12-month follow-ups.
RESULTS: A total of 200 consecutive patients were evaluated. The primary endpoints obtained in the
symptomatic vs. asymptomatic groups were ipsilateral stroke (2.4% vs. 2.7%, p=1.00), ipsilateral parenchymal
hemorrhage (0.8% vs. 0.0%, p=1.00) and major adverse cardiac and cerebrovascular events (4.7% vs. 2.7%,
p=0.71). The secondary endpoints obtained in the symptomatic vs. asymptomatic groups were ipsilateral
ischemic stroke (0.0% vs. 0.0%), ipsilateral parenchymal hemorrhage (0.0% vs. 0.0%), ipsilateral TIA (0.0% vs.
0.0%, p=1.00) and major adverse cardiac and cerebrovascular events (11.2% vs. 4.1%, p=0.11).
CONCLUSIONS: In this retrospective study, carotid artery stenting was similarly safe and effective when
performed as a first-intention treatment in both symptomatic and asymptomatic patients. The study results
comply with the safety requirements from current recommendations to perform carotid artery stenting as an
alternative treatment to carotid endarterectomy.
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& INTRODUCTION
Carotid artery stenosis is associated with approximately
15% of all ischemic strokes (1,2). Carotid endarterectomy
(CEA) is indicated for the revascularization of carotid
stenosis, with the goal of stroke prevention (3). Carotid
artery stenting (CAS) is an emerging alternative to CEA;
however, safety requirements from current guidelines have
recommended CAS only if the rate of periprocedural stroke
or death is , 6% among symptomatic patients or , 3%
among asymptomatic patients (1,2). Despite the increasing
indication of CAS procedures following publication of the
CREST trial results (4), evaluating safety data on CAS
outside of randomized trials is necessary to externally
validate the procedure in daily clinical practice. Moreover,
since the publication of the CREST trial results, no study has
been published that focused specifically on CAS safety
outcomes in Brazil. The aim of the present study is to
evaluate and compare the clinical outcomes of symptomatic
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and asymptomatic patients who had undergone CAS
performed by the interventional neuroradiology team of a
high-volume Brazilian tertiary university hospital.
& MATERIALS AND METHODS
Study design, clinical assessment and workflow
This is a single-center retrospective study. The study
protocol and written informed consent were approved by
the institutional review board, and all patients or their legal
representatives signed the consent forms. We retrospec-
tively evaluated the clinical and radiological data of patients
who underwent CAS for atherosclerotic carotid stenosis
from July 2010 to December 2012. Patients had undergone
CAS if they fulfilled the institutional eligibly criteria, which
are summarized in Table 1. Patients were divided into two
groups: the first group comprised patients presenting
symptomatic carotid stenosis, and the second group
comprised patients presenting asymptomatic carotid steno-
sis. Data on patients who had not undergone CAS and were
clinically managed were not collected.
All patients were examined by certified vascular
neurologists in hospital at the 1-month and at the 12-
month follow-ups. The neurologists measured the neuro-
logical deficit and outcomes using validated Portuguese
versions of the National Institutes of Health Stroke Scale
(NIHSS) and modified Rankin Scale (mRS) (6). The mRS
scores were obtained at hospital admission, 1 month after
treatment, and at the 12-month follow-up. A stroke was
defined as an ischemic neurological deficit (NIHSS score $
4) or aphasia that persisted for more than 24 hours, and
TIA was defined as an ischemic neurological deficit
(NIHSS’ score $ 4) or aphasia that persisted for less than
24 hours. The patients who missed a follow-up were
contacted by telephone.
The primary endpoints were the incidences of ipsilateral
ischemic stroke, ipsilateral parenchymal hemorrhage (iPH)
and major adverse cardiac and cerebrovascular events
(MACCEs) at 30 days. MACCEs are defined as any stroke,
symptomatic myocardial infarction, vascular complication
or death. The secondary endpoints included ipsilateral
ischemic stroke, iPH, ipsilateral TIA and MACCE occurring
between the 1- and 12-month follow-ups.
Carotid artery stenting procedure
All procedures were performed by the interventional
neuroradiology team of our institutional stroke team, which
comprises both training fellows and staff. The CAS
procedure protocol was identical to the procedure that has
already been published (7). We used cerebral embolic
protection devices whenever possible. The recommended
antiplatelet regimen was aspirin (300 mg daily) and
clopidogrel (75 mg daily) at least five days before treatment
or aspirin (300 mg per attack) and clopidogrel (300 mg per
attack) at least four hours before the procedure and
continuing for three months afterward. Aspirin (300 mg
daily) was maintained indefinitely. When an anticoagulant
was indicated for secondary stroke prevention, only 300 mg
daily aspirin was recommended in combination with the
anticoagulant drug; clopidogrel was not indicated. All
patients were discharged 24 hours after treatment if no
contraindication occurred.
Statistical analysis
The continuous variables were presented as the mean
(range, ¡ SD) or median, and Student’s t test or the Mann-
Whitney U test was used, as appropriate. The categorical
variables were presented as numbers and percentages and
compared among groups using the Chi-square or Fisher’s
exact tests, as appropriate. One independent blinded
investigator processed all collected data for the statistical
analysis. SPSS software version 20.0 (Chicago, IL, USA) was
used for the statistical analysis.
& RESULTS
A total of 233 patients who had undergone CAS were
screened; 33 were excluded, and 200 were included. Among
the excluded patients, 28 had undergone CAS during
mechanical thrombectomy for acute ischemic strokes, 2
were treated for carotid stenosis related to radiotherapy, 1
had undergone staged CAS open-heart surgery, and 2 were
lost to follow-up and could not be contacted. Among the 200
patients included, 127 were symptomatic, and 73 were
asymptomatic.
The baseline characteristics of the patients according to
group are summarized in Tables 2 and 3. All the CAS
procedures were successful. Only two patients (1.0%), one
Table 1 - Eligibility criteria.
Inclusion criteria
Patient age $ 18 years
Life expectancy $ 1 year
Symptomatic ICA stenosis $ 50%*
Asymptomatic ICA stenosis $ 60%*
Symptoms were defined as ischemic stroke, transient ischemic attack, hypoperfusion or retinal ischemia
Exclusion criteria
Total occlusion of the target carotid artery
Patients who underwent CAS and mechanical thrombectomy for acute ischemic stroke
Carotid-related severe disabling ischemic stroke (mRS $ 5)
Severe chronic renal insufficiency under non-dialytic management (creatinine clearance # 40 ml/min)
Untreatable bleeding diathesis, hypercoagulable state or refusal of blood transfusion
Contraindication for antiplatelet therapy
Impending major surgery
*Based on the criteria defined by the American Heart Association Stroke Council and defined by the North American Symptomatic Carotid
Endarterectomy Trial (NASCET) (1,5).
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from each group, presented asymptomatic carotid restenosis
(.70%) at the 6- and 12-month follow-ups that required
retreatment. As the two groups were divided based on the
symptomatic status of the patients, a few baseline variables,
carotid related stroke, TIA and mRS, were significantly
different between the groups, as expected. The asympto-
matic group did not present any carotid-related stroke or
TIA, and the mRS grade of this group was significantly
lower than that of the symptomatic group (Table 2). The
other baseline variables that varied significantly between
the two groups were the prevalence rates of coronary heart
disease, contralateral carotid occlusion, and previous
unrelated stroke. Compared with the symptomatic group,
the asymptomatic group had higher prevalence rates of
coronary heart disease (35.6% vs. 16.5%, p= 0.003), previous
unrelated stroke (57.5% vs. 24.4%, p,0.001), and contral-
ateral carotid occlusion (23.3% vs. 7.9%, p= 0.004). A flow-
reversal protection device was used in 12 patients of the
symptomatic group, which was was significantly higher
than that in the asymptomatic group (0 patients, p = 0.004).
All 200 patients were included in the primary analysis.
The overall incidence of ipsilateral stroke was 3.0% (6/200),
and the overall rate of MACCE was 4.0% (8/200) at the 30-
day follow-up (Table 4). The incidence of the primary
endpoints did not differ significantly between the two
groups (Table 4). The incidences of ipsilateral ischemic stroke,
iPH and MACCE for the symptomatic vs. asymptomatic
groups were 2.4% vs. 2.7% (p=1.000), 0.8% vs. 0.0%
(p= 1.000), and 4.7% vs. 2.7% (p=0.713), respectively.
Among the 4 strokes observed in the symptomatic group,
3 were ipsilateral ischemic strokes, and 1 was iPH. The first
ipsilateral stroke occurred immediately after the procedure,
causing significant functional disability (mRS= 4) at the 12-
month follow-up. The second ischemic stroke occurred
6 hours after the procedure, causing moderate patient
disability at the 12-month follow-up (mRS= 3). The third
ischemic stroke occurred after carotid angioplasty and was
caused by an occlusion of the M1 segment of the ipsilateral
middle cerebral artery; the patient presented a moderate
neurological deficit (mRS= 3) at the 12-month follow-up.
The iPH occurred 2 days after the procedure, and the
patient died 10 months later from pneumonia.
The 2 deaths observed in the symptomatic group were
caused by hospital-acquired pneumonia and acute myelo-
dysplastic syndrome. Both of these deaths were unrelated to
cardiovascular complications or to the CAS procedures.
The incidence of clinical secondary outcomes did not
significantly differ between the two groups (Table 4).
During the period between the 1- and 12-month follow-
up, no ipsilateral ischemic stroke, iPH or ipsilateral TIA
were observed. One patient of the symptomatic group had a
cerebellar hemorrhage requiring surgical intervention 7
Table 2 - Patients’ baseline clinical data in each group.
Total (N=200) Symptomatic group (N=127) Asymptomatic group (N=73) p value
Male (n, %) 126 (63) 84 (66.1) 42 (57.5) 0.229
Age (mean, range, SD) 68.5 (35-88, SD: ¡8.82) 68.1 (35-88, SD: ¡9.42) 69.3 (42-84, SD: ¡7.67) 0.31
70 years or older (n, %) 89 (44.5) 53 (41.7) 36 (49.3) 0.306
80 years or older (n, %) 25 (12.5) 17 (13.4) 8 (11) 0.664
Carotid-related stroke (n, %) 102 (51) 102 (80.3) 0 (0) ,0.001
Transient ischemic attack (n, %) 20 (10) 20 (15.7) 0 (0) ,0.001
Retinal infarction (n, %) 5 (2.5) 5 (3.9) 0 (0) 0.161
Previous unrelated stroke (n, %) 73 (36.5) 31 (24.4) 42 (57.5) ,0.001
Coronary heart disease (n, %) 47 (23.5) 21 (16.5) 26 (35.6) 0.003
Congestive heart failure (n, %) 22 (11) 15 (11.8) 7 (9.6) 0.815
Atrial fibrillation (n, %) 10 (5) 6 (4.7) 4 (5.5) 1.000
Peripheral artery disease (n, %) 25 (12.5) 15 (11.8) 10 (13.7) 0.825
Chronic renal insufficiency
(Creatinine clearance # 60 ml/min)
39 (19.5) 24 (18.9) 15 (20.5) 0.853
Chronic obstructive pulmonary
disease (n, %)
15 (7.5) 9 (7.1) 6 (8.2) 0.785
Tobacco smokers (n, %) 119 (59.5) 78 (61.4) 41 (56.1) 0.550
High blood pressure (n, %) 185 (92.5) 117 (92.1) 68 (93.2) 1.000
Hypercholesterolemia (n, %) 148 (74) 94 (74) 54 (74) 1.000
Diabetes mellitus (n, %) 76 (38) 47 (37) 29 (39.7) 0.763
Baseline mRS (mean, SD) 1.7 (0-4, SD: ¡1.31) 1.9 (0-4, SD: ¡1.25) 1.3 (0-4, SD: ¡1.36) 0.009
Table 3 - Patients’ baseline radiologic and procedural data in each group.
Total (N=200) Symptomatic group (N=127)
Asymptomatic group
(N=73) p value
CAS procedure successfully accomplished (n, %) 200 (100) 127 (100) 73 (100) -
Left carotid stenosis (n, %) 98 (49) 61 (48) 37 (50.7) 0.770
Carotid stenosis grade (mean, range, SD,
NASCET %)
74.5 (50-95, SD: ¡14.7) 75.5 (50-95, SD: ¡16.3) 72.8 (60-95, SD: ¡11.44) 0.118
Contralateral carotid occlusion (n, %) 27 (13.5) 10 (7.9) 17 (23.3) 0.004
Cerebral embolic protection (n, %) 191 (95.5) 122 (96.1) 69 (94.5) 0.726
Filter protection device (n, %) 179 (89.5) 110 (86.6) 69 (94.5) 0.095
Flow-reversal device (n, %) 12 (6.0) 12 (9.5) 0 (0.0) 0.004
Pre-dilatation 85 (42.5) 59 (46.5) 26 (35.6) 0.141
Restenosis that was retreated (n, %) 2 (1.0%) 1 (0.8%) 1 (1.3%) 1.000
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months after CAS, and this patient presented a moderate
neurological deficit (mRS= 3) at the 12-month follow-up.
Sixteen patients died, of whom 13 were symptomatic and 3
were asymptomatic. The 3 deaths in the asymptomatic
group were not related to the CAS procedure or to
cerebrovascular or cardiovascular events. In contrast, in
the symptomatic group, one patient who had iPH at the 30-
day follow-up died from pneumonia 10 months later, 2
patients died from acute myocardial infarction, and the
other 10 patients died from causes unrelated to the CAS
procedures or to cerebrovascular or cardiovascular events.
Despite having had strokes that involved only small areas
of infarcted brain tissue, 10.5% (21/200) of the patients had
significant functional disability (mRS= 4) before the proce-
dures; 16 of these patients belonged to the symptomatic
group, and 5 belonged to the asymptomatic group
(p= 0.238). Among the 16 patients (mRS= 4) of the sympto-
matic group, 4 patients (25%) died between the 1- and 12-
month follow-ups, whereas no one among the 5 patients of
the asymptomatic group died (p = 0.532).
& DISCUSSION
In this study, we reported the clinical outcomes of
patients presenting carotid stenosis who underwent CAS
as a first-intention treatment since the publication of the
CREST trial results (3). All procedures were performed by
the interventional neuroradiology staff and fellows at a
high-volume tertiary university hospital that receives
patient referrals from local and regional health facilities.
Our results revealed that the overall incidences of
ipsilateral stroke (3.0%, 6/200) and MACCE (4.0%, 8/200) at
the 30-day follow-up were in accordance with the recom-
mended safety rates for carotid revascularization procedures
(1,2). Moreover, both the primary and secondary endpoints
did not differ significantly between the two groups (Table 4).
Compared with the asymptomatic group, the symptomatic
group had a slightly higher rate of MACCE at the 30-day
follow-up (4.7% vs. 2.7%, p= 0.71), although this difference
was not significant. These MACCE rates were lower than the
recommended safety rates for performing CAS in sympto-
matic (, 6%) and asymptomatic (, 3%) patients (1-3). The
higher MACCE rate in the symptomatic group was expected
because compared with CAS for asymptomatic patients, CAS
for symptomatic patients has been associated with a twofold
higher risk of major complications (1-3). However, the higher
MACCE rates in the symptomatic group were due to 2 deaths
that were not related to the CAS procedures. Therefore,
excluding the 2 unrelated deaths, the rate of ipsilateral stroke
or death between the symptomatic vs. asymptomatic groups
was 3.1% vs. 2.7% (p=1.000), respectively. The secondary
endpoints also showed a higher (but not significantly higher)
rate of MACCE in the symptomatic group compared with the
asymptomatic group (11.2% vs. 4.1%, p=0.11). This finding
was mainly due to the higher rate of death unrelated to
cardiovascular or cerebrovascular complications among the
symptomatic patients during the follow-up period (8.8% vs.
4.1%, p=0.26).
An analysis of the baseline variables showed that carotid-
related stroke or TIA, as per the definition, were present in the
symptomatic group and absent in the asymptomatic group,
which explained the higher mRS scores among the sympto-
matic patients (Table 2). Moreover, the following variables:
previous unrelated stroke, contralateral carotid occlusion, and
coronary heart disease had significantly higher prevalence
rates in the symptomatic group than in the asymptomatic
group. The higher mRS scores of the symptomatic patients
suggests that recent ischemic strokes lead to higher functional
disability scores than do chronic unrelated strokes or
contralateral carotid occlusions (Table 2). Another interesting
finding was that despite the higher frequency of coronary
heart disease in the asymptomatic group, no patient of that
group suffered a myocardial infarction, whereas in the
symptomatic group with a lower frequency of baseline
coronary heart disease, 2 deaths from myocardial infarction
were observed during the 12-month follow-up.
Our results revealed that CASwas safe when indicated as a
first-intention revascularization strategy performed during
daily clinical practice at a high-volume center outside of a
Table 4 - Clinical outcomes per group at the 1- and 12-month follow-ups.
During the 30-day follow-up Total (N=200)
Symptomatic group
(N=127)
Asymptomatic group
(N=73)
One-tailed
p value
Two-tailed
p value
Ipsilateral ischemic stroke (n, %) 5 (2.5) 3 (2.4) 2 (2.7) 0.602 1.000
Ipsilateral parenchymal hemorrhage (n, %) 1 (0.5) 1 (0.8) 0 (0.0) 0.635 1.000
Any stroke (n, %) 6 (3.0) 4 (3.1) 2 (2.7) 0.618 1.000
Ipsilateral transient ischemic attack (n, %) 3 (1.5) 3 (2.4) 0 (0.0) 0.254 0.301
Symptomatic myocardial infarction (mean, %) 0 (0.0) 0 (0.0) 0 (0.0) - -
Deaths (n, %) 2 (1.0) 2 (1.6) 0 (0.0) 0.412 0.534
MACCE (n, %) 8 (4.0) 6 (4.7) 2 (2.7) 0.389 0.713
mRS (mean, range, SD) 2.03 (0-6, SD: ¡1.51) 2.03 (0-6, SD: ¡1.51) 1.49 (0-6, SD: ¡1.45) - 0.030
Between the 1- and 12-month follow-ups Total (N=198)
Symptomatic group
(N=125)
Asymptomatic group
(N=73)
One-tailed
p value
Two-tailed
p value
Ipsilateral ischemic stroke (n, %) 0 (0.0) 0 (0.0) 0 (0.0) - -
Ipsilateral parenchymal hemorrhage (n, %) 0 (0.0) 0 (0.0) 0 (0.0) - -
Any stroke (n, %) 1 (0.5) 1 (0.8) 0 (0.0) 0.635 1.000
Ipsilateral transient ischemic attack (n, %) 0 (0.0) 0 (0.0) 0 (0.0) - -
Symptomatic myocardial infarction (mean, %) 2 (1.0) 2 (1.6) 0 (0.0) 0.412 0.534
Deaths (n, %) 16 (8.0) 13 (10.4) 3 (4.1) 0.094 0.175
MACCE (n, %) 17 (8.5) 14 (11.2) 3 (4.1) 0.068 0.115
mRS (mean, range, SD) 2.15 (0-6, SD: ¡1.70) 2.29 (0-6, SD: ¡1.74) 1.53 (0-6, SD: ¡1.54) - 0.006
(mRS) modified Rankin Scale; (MACCE) major adverse cardiac and cerebrovascular events (MACCE), defined as any stroke, symptomatic myocardial
infarction, vascular complication or death.
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randomized trial. Importantly, previous carotid revascular-
ization randomized trials, which served as the inspiration for
the current procedural safety limits, had more restricted
eligibility panels than those of our institutional protocol (1,3)
(Table 1). In other words, we observed similar periprocedural
safety outcome rates to those of previous controlled carotid
trials in a real clinical care context in which CAS was
indicated as the first-intention treatment. The policy of
indicating CAS as a first-intention therapy plays a relevant
methodological role in the interpretation of the results
obtained because important selection biases were avoided
(8). In addition, because patients were evaluated by certified
vascular neurologists, the incidence of stroke observed in this
study was likely not influenced by clinical assessment bias as
reported in other surgical studies (9).
The good results obtained in this study may be explained
by a sum of the following factors: the use of embolic
protection devices (10,11), the use of a double antiplatelet
regimen (1-3), and the high-volume center setting (12,13). Our
findings underscore the value of performing a high volume of
CAS procedures and amore experienced neurointerventional
team on the outcomes obtained. Moreover, we stress the
importance of a CAS reference center for achieving good
outcomes as opposed to the common Brazilian reality of care,
in which CAS procedures are performed at multiple distantly
arranged low-volume hospitals.
The major limitations of the study are the small sample
size, the non-randomized and retrospective design, and the
lack of clinical data on patients who were clinically
managed and did not undergo CAS.
In this retrospective study conducted at a high-volume
Brazilian interventional neuroradiology center, CAS was
similarly safe and effective when performed as a first-
intention treatment in both symptomatic and asymptomatic
patients. The study results comply with the safety require-
ments from the current recommendations to perform CAS
as an alternative treatment to CEA.
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